NCT03008122View on ClinicalTrials.gov

Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

March 21, 2017

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions
Zika Virus Infection
Interventions
OTHER

Placebo

Placebo

BIOLOGICAL

Zika Virus Purified Inactivated Vaccine (ZPIV)

Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.

Trial Locations (1)

00716

Ponce School of Medicine CAIMED Center, Ponce

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03008122 - Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area | Biotech Hunter | Biotech Hunter